AVBP (ArriVent BioPharma) Kacepetan wutah bathi saben saham ing taun lumaku

Staff shortage risks have been minimized through an option program for oncologists, and the GURU.Markets terminal provides a chart of annual EPS growth, where the current value is 9.70. The absence of current revenue due to clinical status is offset by high trial transparency and management's deep expertise in FDA matters, ensuring the fundamental stability of ArriVent BioPharma, Inc (AVBP).

This indicator measures the annual dynamics of net income per share, reflecting the growth or decline rates of business profitability in percentage terms. By analyzing the relative EPS growth over 12 months, an investor can assess the impact of ArriVent BioPharma, Inc (AVBP) oncology drug clinical trial outcomes on capitalization, given the high FDA regulatory risks and pressure from competitors.